• IBA – ACQUISITION OF OWN SHARES

    المصدر: Nasdaq GlobeNewswire / 19 مايو 2025 12:40:00   America/New_York

    Immediate Release – May 19th, 2025

    Louvain-la-Neuve, Belgium, May 19th, 2025 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on March 24th, 2025.

    Under this program, IBA has requested a financial intermediary to repurchase up to 650,000 IBA ordinary shares on its behalf under the terms of a mandate with validity until December 31st, 2025, effective as from March 25th, 2025, to cover the company’s obligations under long-term incentive plans for management and certain members of its personnel.

    In the framework of this share buyback program, IBA repurchased 26,500 IBA shares on Euronext Brussels in the period from May 13th, 2025 up to and including May 19th, 2025, as follows:


     Trade dateShares purchasedAverage priceMin priceMax priceBuyback amount 
     13-05-250     
     14-05-253,00011.58 €11.54 €11.60 €34,752.30 € 
     15-05-257,00011.41 €11.34 €11.50 €79,888.20 € 
     16-05-257,00011.38 €11.34 €11.44 €79,645.30 € 
     19-05-259,50011.20 €11.16 €11.36 €106,440.85 € 
     TOTAL26,50011.35 €11.16 €11.60 €300,726.65 € 


    The total number of shares purchased under this program therefore amounts to 582,849, following this eighth week of execution. As a result, the current situation with respect to treasury shares (held directly by IBA SA and indirectly through its subsidiary IBA Investments SRL) is the following :


      SharesVoting rights
    IBA Investments SRL51,973103,946
    IBA SA 896,428962,851
    Total - Treasury shares948,4011,066,797
    Total - Issued shares30,282,21840,514,366
    Treasury shares in %3.13%2.63%


    About IBA 
    IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered as the most advanced form of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,100 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

    IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

    More information can be found at: www.iba-worldwide.com

    Contact person

    IBA
    Thomas Pevenage
    Investor Relations
    investorrelations@iba-group.com

    Attachment


شارك على،